Поиск по каталогу |
(строгое соответствие)
|
- Профессиональная
- Научно-популярная
- Художественная
- Публицистика
- Детская
- Искусство
- Хобби, семья, дом
- Спорт
- Путеводители
- Блокноты, тетради, открытки
EGFR expression and the role of Gefitinib in Oral cavity lesions. Expression of EGFR in Premalignant and Malignant lesions of the oral cavity and evaluating the role of Gefitinib
В наличии
Местонахождение: Алматы | Состояние экземпляра: новый |
Бумажная
версия
версия
Автор: Umesh Velu,Awadesh Kumar Dixit and Shambunath Prasad
ISBN: 9783659373558
Год издания: 2013
Формат книги: 60×90/16 (145×215 мм)
Количество страниц: 56
Издательство: LAP LAMBERT Academic Publishing
Цена: 21130 тг
Положить в корзину
Способы доставки в город Алматы * комплектация (срок до отгрузки) не более 2 рабочих дней |
Самовывоз из города Алматы (пункты самовывоза партнёра CDEK) |
Курьерская доставка CDEK из города Москва |
Доставка Почтой России из города Москва |
Аннотация: Oral Cavity cancer is the 10th most common malignancy globally. EGFR is a glycoprotein encoded by a gene located on chromosome 7p12. Stimulation of EGFR will activate an intracellular signalling pathway, leading to the inhibition of apoptosis, activation of cell proliferation and angiogenesis, as well as an increase in metastatic spread potential. In premalignant lesions EGFR can be considered as an early marker of a cell proliferation on cell differentiation as well as early marker of epithelial dysplasia and onset of cancer in oral premaligant lesions. Hence cancers of oral cavity can be prevented and progress of carcinogenisis may be stopped at a early stage. EGFR evaluation can be used as a Screening tool in premalignant lesions to determine its malignant potential. In Malignant it has been seen that there is better response to treatment when EGFR Inhibitor Gefitinib was combined to the standard regimen of CCRT in Locally advanced Oral cavity malignant lesions.
Ключевые слова: Oncology, Radiotherapy, EGFR, head and neck cancers, Oral cavity Cancers, gefitinib